_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
The hospital through its network performs more than 10,000 joint replacement surgeries annually
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The medicine is now approved for eight indications across five different types of cancer in China.
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
Subscribe To Our Newsletter & Stay Updated
